Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients

Table 4

Absolute changes in HMGB1, BASDAI, BASFI, ASDAS-ESR, ASDAS-CRP, ESR, and CRP in the two follow-up therapeutic AS groups.

	Anti-TNF	SASP + NSAIDs
HMGB1 change, mean (SD), ng/mL
1 month	(22.25)	1.52 (24.99)
3 months	(23.70)	(19.89)
6 months	(28.68)	(25.30)
BASDAI change, mean (SD)
1 month	(1.51)	(0.51)
3 months	(1.61)	(0.77)
6 months	(1.51)	(1.16)
BASFI change, mean (SD)
1 month	(1.56)	(0.61)
3 months	(1.65)	(1.00)
6 months	(1.69)	(1.17)
ASDAS-ESR change, mean (SD)
1 month	(1.07)	(0.59)
3 months	(0.86)	(0.62)
6 months	(0.89)	(0.69)
ASDAS-CRP change, mean (SD)
1 month	(0.79)	(0.81)
3 months	(0.83)	(1.00)
6 months	(0.63)	(0.96)
ESR change, mean (SD), mm/h
1 month	(24.61)	(19.22)
3 months	(25.91)	(18.18)
6 months	(26.69)	(22.47)
CRP change, mean (SD), mg/L
1 month	(12.99)	(18.54)
3 months	(25.99)	(25.57)
6 months	(28.41)	(26.32)

⁢ versus baseline. ⁢ versus SASP + NSAIDs.